Will MetLife Egypt and AXA Egypt and Bupa Egypt cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Awiqli is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDA?

The EDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Egyptian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Egyptian Medical Syndicate and the EDA verifies the active license; the EDA application records both the prescribing physician and the dispensing facility.

Can I receive Awiqli at home?

The dispensing facility must be Egyptian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 330 to 420 per month. Delivered quote within 24h.Get my quote

Awiqli access in Egypt: the EDA named-patient pathway

How patients in the Arab Republic of Egypt legally obtain Awiqli (insulin icodec) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Egypt access Awiqli (insulin icodec) for improvement of glycaemic control in adults with diabetes mellitus, dosed once weekly through the EDA named-patient pathway, an Egyptian Drug Authority-administered mechanism that allows an Egyptian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in EGP.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Awiqli reaches patients in Egypt

Awiqli (insulin icodec, a once-weekly basal insulin analogue from Novo Nordisk that achieves a roughly week-long half-life through reversible albumin binding and reduced enzymatic clearance) was authorised by the European Medicines Agency in April 2024 for the treatment of diabetes mellitus in adults per the European Public Assessment Report at ema.europa.eu/medicines/human/EPAR/awiqli, and by Health Canada in March 2024 per the Health Canada Drug Product Database at health-products.canada.ca/dpd-bdpp. The US FDA Endocrinologic and Metabolic Drugs Advisory Committee voted against approval for type 1 diabetes in May 2024 and the FDA issued a Complete Response Letter for the type 2 diabetes indication in July 2024 per Novo Nordisk public investor disclosure; FDA approval status for Awiqli remains pending in the United States as of 2026-06-01 and the US distribution channel is restricted. Egyptian patients accessing Awiqli through Reserve Meds therefore source from the EMA or Health Canada channels rather than the FDA channel. The Egyptian Drug Authority registered-drug database at eservices.edaegypt.gov.eg shows no public registration record for insulin icodec or Awiqli as of 2026-06-01. Egyptian patients access the drug through the Personal Importation of Unregistered Medicines pathway operated by the EDA Central Administration for Pharmaceutical Affairs under Pharmacy Practice Law No. 127 of 1955, Health Minister Decree No. 296 of 2009, and the post-2019 EDA framework at edaegypt.gov.eg. The treating Egyptian-licensed endocrinologist or diabetologist issues a stamped medical report documenting the type 2 diabetes diagnosis, the prior basal-insulin regimen, the HbA1c trend, the planned weekly dose with the conversion from prior daily basal insulin (typically multiply daily basal dose by 7 with a 50% loading-dose adjustment in the first week per the EMA label), and the rationale referencing the ONWARDS phase 3a program at clinicaltrials.gov. EDA does not publish a fixed processing-time SLA; reporting indicates one to three weeks when documentation is complete. Each shipment requires a fresh permit with convention up to a three-month supply.

Where Awiqli is dispensed in Egypt

Awiqli is a once-weekly subcutaneous injection administered at home by the patient with quarterly endocrinology review of HbA1c, fasting glucose, continuous-glucose-monitoring data where available, and hypoglycaemia surveillance. The Egyptian tertiary endocrinology and diabetes centres routinely involved in inhaled-naive specialty-insulin handling and named-patient imports include the National Institute of Diabetes and Endocrinology in Cairo at mohp.gov.eg; Cairo University Hospitals (Kasr Al-Ainy) Department of Endocrinology and Diabetes at kasralainy.edu.eg; Ain Shams University Hospitals Diabetes and Endocrinology Unit in Cairo; Alexandria University Hospitals Department of Internal Medicine and Endocrinology at alexmed.edu.eg; and Mansoura University Specialised Medical Hospital Diabetes Unit at mans.edu.eg. Private tertiary centres equipped for diabetes outpatient care and named-patient imports include Cleopatra Hospitals Group at cleopatrahospital.com, As-Salam International Hospital, and the Egyptian Diabetes Association affiliated centres at eda.com.eg. The National Institute of Diabetes and Endocrinology and the Cairo University endocrinology service are the most frequent dispensing nodes for novel-insulin imports.

What Awiqli costs in Egypt

The European reference price for Awiqli is reported by Novo Nordisk through the European Public Assessment Report channel and the Danish Medicines Agency at approximately EUR 100 to EUR 130 per FlexTouch 700 unit pre-filled pen depending on the EU member state, with annual drug-only spend in the range of EUR 1,500 to EUR 2,200 at a typical 250 to 400 unit weekly maintenance dose; the EMA EPAR documents the strengths and pack sizes at ema.europa.eu/medicines/human/EPAR/awiqli. Converted at the European Central Bank reference rate, the USD equivalent is approximately USD 1,650 to USD 2,420 per year. Price snapshot: 2026-06-01. No public local-currency price for Awiqli in Egyptian Pounds is observed in the EDA pricing committee output or the Unified Procurement Authority disclosures at upa.gov.eg as of 2026-06-01; do not estimate. Cost layers beyond the drug itself include refrigerated 2 to 8 degrees Celsius cold-chain logistics from the EU or Canada source channel (Awiqli is a temperature-sensitive biological product), the nominal EDA permit and customs duties, dispensing fees, and the Reserve Meds concierge fee itemised separately on every firm quote.

Funding and access barriers for Awiqli in Egypt

Diabetes care in Egypt is a recognised priority of the MOHP given the high national prevalence per the International Diabetes Federation Atlas at diabetesatlas.org. The Universal Health Insurance Authority (UHIA) at uhia.gov.eg covers diabetes chronic-disease management in implementation governorates including basal insulin therapy under the joint formulary with the Unified Procurement Authority; specific reimbursement of insulin icodec is not yet on the UHIA list as of 2026-06-01 and conventional daily basal insulins (insulin glargine, insulin degludec) are the standard reimbursed analogues. The Health Insurance Organisation (HIO) in pre-UHI governorates covers basal-insulin therapy for enrolled employees and pensioners on the HIO formulary. Major private insurers (MetLife Egypt, AXA Egypt, Allianz Egypt, Misr Insurance, GlobeMed Egypt as TPA, Med Net) cover daily basal insulins on most retail and group plans, often with prior authorisation; weekly insulin icodec is a newer category and coverage decisions are case by case. The Egyptian Diabetes Association and the Egyptian Society of Endocrinology provide the clinical-society anchor families can reference for clinical-rationale support. Out-of-pocket spending dominates per World Bank data at data.worldbank.org; for patients seeking insulin icodec specifically the dominant pattern is self-pay because the EU-equivalent annual cost is moderate compared with specialty oncology, though materially higher than locally available daily basal-insulin analogues. The hypoglycaemia-monitoring infrastructure (CGM access, glucometer strip availability) is a parallel access factor families plan around because weekly dosing changes hypoglycaemia patterns.

Recent regulatory and access news for Awiqli

Novo Nordisk reported continued ONWARDS-program post-marketing data through 2025 covering type 2 diabetes outcomes with insulin icodec versus daily basal insulin comparators at the American Diabetes Association Scientific Sessions and the European Association for the Study of Diabetes Annual Meeting per published manuscripts on PubMed at pubmed.ncbi.nlm.nih.gov. The European Medicines Agency expanded the EMA-authorised label in 2025 covering paediatric type 1 diabetes per the updated European Public Assessment Report at ema.europa.eu/medicines/human/EPAR/awiqli, broadening the in-label patient population an Egyptian endocrinologist can cite. The US FDA Complete Response Letter of July 2024 remains the binding US-status reference, and Novo Nordisk has continued post-CRL discussion with the FDA per public investor disclosure; the agency has not approved Awiqli in the United States as of 2026-06-01. UHIA and the Unified Procurement Authority continued the phased UHI rollout per UHIA bulletins at uhia.gov.eg. No drug-specific EDA bulletin for insulin icodec or Awiqli over the last 12 months has been observed as of 2026-06-01.

Where Reserve Meds fits in Awiqli cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDA, and we do not replace your dispensing pharmacy. For Awiqli specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Egypt, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Awiqli case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Awiqli is administered subcutaneously once weekly; titration follows a fasting glucose-guided algorithm and the patient is educated on weekly dosing day discipline and missed-dose recovery.

Next step

If your Egyptian physician has prescribed Awiqli and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Awiqli case Or message us on WhatsApp